Sharon Moisiuk

Suggest Changes
Learn More
BACKGROUND Infants born at 33 through 35 completed weeks of gestation (33-35GA) are at risk for severe respiratory syncytial virus (RSV) infection, and palivizumab prophylaxis lowers hospitalizations(More)
  • 1